A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...
One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.
After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab ... Sesinando Daval-Santos IV, for collection of data, supervision of research, provision of trial materials ...
VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
In the article that accompanies this editorial, 7 KEYNOTE-789, a randomized phase III trial of carboplatin- or cisplatin-pemetrexed-pembrolizumab versus carboplatin- or cisplatin-pemetrexed in 492 ...
Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...
1 The trial (NCT05499390) included patients with previously untreated, PD-L1 positive, stage IIIB-IV NSCLC. The patients received the PD-1/VEGF bispecific antibody ivonescimab (n=198) or pembrolizumab ...
COPENHAGEN, Denmark I September 16, 2024 I Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback